浙江拱东医疗器械股份有限公司 2025年年度业绩预告

Core Viewpoint - The company, Zhejiang Gongdong Medical Instrument Co., Ltd., anticipates a significant decline in net profit for the fiscal year 2025, projecting a decrease of 67.37% to 74.36% compared to the previous year [2][3]. Group 1: Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 44 million to 56 million yuan for 2025, a decrease of 115.63 million to 127.63 million yuan from the previous year [2][3]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between 54 million to 66 million yuan, reflecting a reduction of 102.15 million to 114.15 million yuan year-on-year [3]. Group 2: Previous Year’s Performance - In the previous year, the total profit was 188.74 million yuan, with a net profit attributable to shareholders of the parent company at 171.63 million yuan, and a net profit excluding non-recurring gains and losses at 168.15 million yuan [4]. Group 3: Reasons for Performance Decline - The decline in performance is attributed to several factors: - Goodwill Impairment: The company anticipates a goodwill impairment of approximately 24 million to 30 million yuan due to the underperformance of its subsidiary, Trademark Plastics Inc., influenced by international trade policies and shipping cost fluctuations [4][5]. - Decrease in Gross Margin: The gross margin has declined due to slowed demand for certain products as a result of U.S. tariff policies and domestic medical procurement policies [5]. - Exchange Rate Fluctuations: Financial expenses related to exchange rate fluctuations have increased, contributing to the decline in net profit [6]. - Non-operating Losses: The company incurred an investment loss of approximately 11 million yuan due to additional investments in a controlled entity, impacting non-operating gains and losses [7].